MCID: INT395
MIFTS: 47

Intracranial Meningioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Intracranial Meningioma

MalaCards integrated aliases for Intracranial Meningioma:

Name: Intracranial Meningioma 12 54
Meningioma 44

Classifications:



External Ids:

Disease Ontology 12 DOID:0080842
MeSH 44 D008579
NCIt 50 C4656
SNOMED-CT 67 302820008
UMLS 70 C0349604

Summaries for Intracranial Meningioma

Disease Ontology : 12 A meningioma that arises within the cranial cavity.

MalaCards based summary : Intracranial Meningioma, also known as meningioma, is related to clear cell meningioma and neurofibromatosis, type i. An important gene associated with Intracranial Meningioma is PGR (Progesterone Receptor), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Thrombin and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include pituitary, spinal cord and breast, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and endocrine/exocrine gland

Related Diseases for Intracranial Meningioma

Diseases related to Intracranial Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1155)
# Related Disease Score Top Affiliating Genes
1 clear cell meningioma 31.8 PGR MKI67
2 neurofibromatosis, type i 31.3 MSH2 MLH1 CDKN2A
3 meningioma, familial 30.6 PGR PCNA MKI67 IGF2 ESR1 CDKN2A
4 acoustic neuroma 30.3 PCNA MSH2 MGMT
5 benign meningioma 29.8 PGR PCNA MKI67
6 anaplastic astrocytoma 29.8 MLH1 MGMT CDKN2A
7 gliosarcoma 29.7 MSH2 MGMT CDKN2A
8 gliofibroma 29.7 MGMT CDKN2A
9 mismatch repair cancer syndrome 29.6 MSH2 MLH1
10 papilloma 29.6 PCNA IGF2 GSTP1 CDKN2A
11 pheochromocytoma 29.6 MSH2 IGF2 ESR1 CDKN2A
12 lymphangioleiomyomatosis 29.5 PGR IGF2 ESR1
13 basal cell carcinoma 29.5 MSH2 MLH1 MKI67 CDKN2A
14 intravenous leiomyomatosis 29.5 PGR ESR1
15 mismatch repair cancer syndrome 1 29.5 MSH2 MLH1
16 adenoma 29.4 MSH2 MLH1 MKI67 MGMT CDKN2A
17 giant cell glioblastoma 29.4 MSH2 MGMT CDKN2A
18 oligodendroglioma 29.4 PCNA MSH2 MLH1 MGMT CDKN2A
19 bilateral breast cancer 29.3 PGR MLH1 ESR1 CDKN2A
20 familial adenomatous polyposis 29.3 MSH2 MLH1 MGMT GSTP1
21 peritoneal mesothelioma 29.3 PGR ESR1 CDKN2A
22 in situ carcinoma 29.2 PGR ESR1 CDKN2A
23 cervical squamous cell carcinoma 29.2 MLH1 MKI67 CDKN2A
24 leiomyosarcoma 29.2 PGR IGF2 ESR1 CDKN2A
25 prostatic hypertrophy 29.2 PGR PCNA ESR1
26 inverted papilloma 29.2 PCNA MKI67 CDKN2A
27 breast adenocarcinoma 29.1 PGR MGMT GSTP1 ESR1
28 esophageal cancer 29.1 MLH1 MGMT IGF2 GSTP1 CDKN2A
29 li-fraumeni syndrome 28.9 MSH2 MLH1 IGF2 ESR1 CDKN2A
30 breast ductal carcinoma 28.9 PGR MKI67 ESR1
31 gallbladder cancer 28.9 MSH2 MLH1 MGMT ESR1 CDKN2A
32 lynch syndrome 28.9 MSH2 MLH1 MGMT GSTP1 CDKN2A
33 skin melanoma 28.8 PCNA MLH1 MKI67 CDKN2A
34 rhabdomyosarcoma 28.6 MSH2 MLH1 MGMT IGF2 ESR1 CDKN2A
35 skin carcinoma 28.5 PGR MSH2 MLH1 GSTP1 ESR1 CDKN2A
36 endometrial hyperplasia 28.3 PGR MSH2 MLH1 MKI67 ESR1
37 leiomyoma 28.3 PGR PCNA MKI67 IGF2 ESR1
38 prostate cancer 27.8 PGR PCNA MSH2 MKI67 IGF2 GSTP1
39 hepatocellular carcinoma 27.7 MSH2 MKI67 MGMT IGF2 GSTP1 ESR1
40 breast cancer 27.2 PGR PCNA MSH2 MLH1 MKI67 IGF2
41 endometrial cancer 26.8 PGR PCNA MSH2 MLH1 MKI67 MGMT
42 spinal meningioma 11.6
43 brain meningioma 11.4
44 rhabdoid meningioma 11.4
45 intraorbital meningioma 11.3
46 childhood brain meningioma 11.3
47 optic nerve sheath meningioma 11.2
48 hemangiopericytoma, malignant 11.2
49 cavernous sinus meningioma 11.2
50 tuberculum sellae meningioma 11.2

Graphical network of the top 20 diseases related to Intracranial Meningioma:



Diseases related to Intracranial Meningioma

Symptoms & Phenotypes for Intracranial Meningioma

GenomeRNAi Phenotypes related to Intracranial Meningioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.02 ESR1 IGF2 MKI67 MSH2 PCNA

MGI Mouse Phenotypes related to Intracranial Meningioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.03 CDKN2A DVL3 ESR1 IGF2 MGMT MLH1
2 hematopoietic system MP:0005397 10.01 CDKN2A DVL3 ESR1 IGF2 MLH1 MSH2
3 immune system MP:0005387 9.97 CDKN2A DVL3 ESR1 IGF2 MLH1 MSH2
4 mortality/aging MP:0010768 9.91 CDKN2A DVL3 ESR1 IGF2 MGMT MLH1
5 integument MP:0010771 9.87 CDKN2A ESR1 GSTP1 IGF2 MLH1 MSH2
6 neoplasm MP:0002006 9.7 CDKN2A ESR1 GSTP1 MGMT MLH1 MSH2
7 no phenotypic analysis MP:0003012 9.5 CDKN2A ESR1 IGF2 MGMT MKI67 PCNA
8 respiratory system MP:0005388 9.1 CDKN2A DVL3 ESR1 IGF2 MGMT MLH1

Drugs & Therapeutics for Intracranial Meningioma

Drugs for Intracranial Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic Acid Approved Phase 4 1197-18-8 5526
3
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
4
Racepinephrine Approved Phase 4 329-65-7 838
5
Prilocaine Approved Phase 4 721-50-6 4906
6
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
7 Fibrin Tissue Adhesive Phase 4
8 Neurotransmitter Agents Phase 4
9 Antifibrinolytic Agents Phase 4
10 Coagulants Phase 4
11 Hemostatics Phase 4
12 Anesthetics Phase 4
13 Anesthetics, Local Phase 4
14 Pharmaceutical Solutions Phase 4
15 Vasoconstrictor Agents Phase 4
16 Respiratory System Agents Phase 4
17 Adrenergic alpha-Agonists Phase 4
18 Anti-Asthmatic Agents Phase 4
19 Adrenergic beta-Agonists Phase 4
20 Epinephryl borate Phase 4
21 Adrenergic Agonists Phase 4
22 Adrenergic Agents Phase 4
23 Mydriatics Phase 4
24 Sympathomimetics Phase 4
25 Bronchodilator Agents Phase 4
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
27
Cisatracurium Approved Phase 3 96946-41-7 62887
28
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
29
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
30
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
31
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
32
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
33
Aminolevulinic acid Approved Phase 3 106-60-5 137
34 Antihypertensive Agents Phase 3
35 Contraceptives, Postcoital Phase 3
36 Contraceptives, Oral Phase 3
37 Contraceptive Agents Phase 3
38 Progestins Phase 3
39 Photosensitizing Agents Phase 3
40 Dermatologic Agents Phase 3
41
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
42
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
43
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
44
Hydroxyurea Approved Phase 2 127-07-1 3657
45
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
46
Verapamil Approved Phase 2 52-53-9 2520
47
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
48
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
49
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
50
Mesna Approved, Investigational Phase 2 3375-50-6 598

Interventional clinical trials:

(show top 50) (show all 146)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study Not yet recruiting NCT04386642 Phase 4 Tranexamic acid;Placebo
5 Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function Evaluated With Diaphragm Thickening Fraction Not yet recruiting NCT04756050 Phase 4 Bupivacaine HCl 0.5% Injectable Solution;Prilocaine HCl % 2 injectable solution;adrenaline amp 0.5mg
6 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
7 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
8 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Completed NCT03558516 Phase 3 Magnesium group;Normal saline group
9 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
10 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
11 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas Recruiting NCT04305470 Phase 3 Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
12 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
13 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
14 Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area Unknown status NCT01849484 Phase 2
15 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
16 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
17 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
18 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
19 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
20 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
21 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
22 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
23 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Completed NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
24 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
25 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
26 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Completed NCT00006119 Phase 2 hydroxyurea
27 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
28 A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas Completed NCT02831257 Phase 2 AZD2014
29 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
30 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
31 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
32 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
33 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
34 Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes Completed NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
35 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
36 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
37 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib
38 A Phase 2 Study of Abemaciclib in Patients With Recurrent Brain Tumors Recruiting NCT03220646 Phase 2 abemaciclib;abemaciclib
39 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2
40 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg
41 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
42 A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting NCT04082520 Phase 2 Lutetium Lu 177 Dotatate
43 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
44 A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma Recruiting NCT04659811 Phase 2 Pembrolizumab
45 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab
46 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
47 Phase II, Dosimetry Guided, Peptide Receptor Radiotherapy (PRRT) Using 90Y-DOTA tyr3-Octreotide (90Y-DOTATOC) in Children and Adults With Neuroendocrine and Other Somatostatin Receptor Positive Tumors Recruiting NCT03273712 Phase 2 Amino Acids
48 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
49 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas Active, not recruiting NCT00895622 Phase 2
50 Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study Active, not recruiting NCT00626730 Phase 2

Search NIH Clinical Center for Intracranial Meningioma

Cochrane evidence based reviews: meningioma

Genetic Tests for Intracranial Meningioma

Anatomical Context for Intracranial Meningioma

MalaCards organs/tissues related to Intracranial Meningioma:

40
Pituitary, Spinal Cord, Breast, Brain, Thyroid, Pineal, Bone

Publications for Intracranial Meningioma

Articles related to Intracranial Meningioma:

(show top 50) (show all 15063)
# Title Authors PMID Year
1
[Immunohistochemical expression of progesterone receptor in relationship with histological grade and risk of relapses in intracranial meningiomas]. 54 61
19603293 2009
2
Ki-67 and vascular endothelial growth factor expression in intracranial meningiomas in dogs. 54 61
19175733 2009
3
Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. 61 54
18418552 2008
4
Proliferation potential of spinal meningiomas. 54 61
15926055 2006
5
DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases. 61 54
12204057 2002
6
Expression of the proliferating cell nuclear antigen and clinicopathological features in intracranial meningiomas. 54 61
11386825 2001
7
Significance of proliferating cell nuclear antigen in predicting recurrence of intracranial meningioma. 54 61
8613841 1996
8
Growth rate of intracranial meningioma: tumor doubling time and proliferating cell nuclear antigen staining index. 54 61
7623949 1995
9
Immunohistochemical study of estrogen receptor-related antigen, progesterone and estrogen receptors in human intracranial meningiomas. 54 61
8033047 1994
10
Immunohistochemical expression of proliferating cell nuclear antigen (PCNA) in intracranial glioma and meningioma. 61 54
7911730 1994
11
Correlation between sex hormone receptors and peritumoral edema in intracranial meningiomas. 54 61
7965139 1994
12
Chrysophanol inhibits the osteoglycin/mTOR and activats NF2 signaling pathways to reduce viability and proliferation of malignant meningioma cells. 61
33622177 2021
13
Case report 68Ga-DOTATATE of optic nerve sheath meningioma. 61
33748535 2021
14
KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo. 61
33652084 2021
15
Proton therapy: A therapeutic opportunity for aggressive pediatric meningioma. 61
33682333 2021
16
Intracranial long-term complications of radiation therapy: an image-based review. 61
33392738 2021
17
The Stanford stereotactic radiosurgery experience on 7000 patients over 2 decades (1999-2018): looking far beyond the scalpel. 61
33799297 2021
18
Novel histopathological classification of meningiomas based on dural invasion. 61
32546547 2021
19
A cohort study on adult hematological malignancies and brain tumors in relation to magnetic fields from indoor transformer stations. 61
33601135 2021
20
Demographic and socioeconomic disparities of benign and malignant spinal meningiomas in the United States. 61
33068594 2021
21
Value of KI-67/MIB-1 labeling index and simpson grading system to predict the recurrence of who grade I intracranial meningiomas compared to who grade II. 61
33775343 2021
22
WHO classification of meningiomas-A single institutional experience. 61
33144180 2021
23
Evolution of the neurosurgical management of progestin-associated meningiomas: a 23-year single-center experience. 61
33449307 2021
24
Cognitive reserve protects language functions in patients with brain tumours. 61
33524456 2021
25
Postpartum Recovery From Meningioma-Related Oculomotor Palsy. 61
33706360 2021
26
Late malignant transformation of anaplastic meningioma 18 years after primary surgery: A case report. 61
33775317 2021
27
Clinical Outcome and Recurrence After Meningioma Surgery: An Experience from a Developing Country, Nepal. 61
33359878 2021
28
In-Hospital Complications After Surgery in Elderly Patients with Asymptomatic or Minor Symptom Meningioma: A Nationwide Registry Study. 61
33444840 2021
29
Cavernous Sinus Meningioma Resection Through Orbitozygomatic Craniotomy. 61
33515796 2021
30
The histopathological diagnosis of atypical meningioma: glass slide versus whole slide imaging for grading assessment. 61
33305338 2021
31
Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients. 61
33528717 2021
32
Resected atypical meningioma relapsed to anaplastic meningioma during luteinizing hormone-releasing hormone agonist therapy. 61
33190809 2021
33
Intraparenchymal supratentorial papillary meningioma: a case report. 61
29564936 2021
34
Orbital decompressive effect of endoscopic transorbital surgery for sphenoorbital meningioma. 61
33226438 2021
35
[Retracted] α3β1 integrin promotes radiation-induced migration of meningioma cells. 61
33655324 2021
36
Somatostatin Receptor-Targeted Radiopeptide Therapy in Treatment-Refractory Meningioma: Individual Patient Data Meta-analysis. 61
32859705 2021
37
Effect of Surgeon Experience on Surgical Outcome of 80-Year-Old or Older Intracranial Meningioma Patients. 61
33422717 2021
38
A rare case of parasagittal meningioma causing isolated foot drop: case report and review of the literature. 61
31786742 2021
39
Trends in the Management Paradigms of Intracranial Meningioma. 61
33777636 2021
40
Case report of primary dural lymphoma mimicking a cerebellar meningioma and brief review of literature. 61
31301042 2021
41
Rate of incidental central nervous system meningioma detected in patients undergoing 18F-fluciclovine PET/CT imaging for evaluation of prostate cancer. 61
33741867 2021
42
Neurosarcoidosis Masquerading as Giant Cell Arteritis With Incidental Meningioma. 61
32441899 2021
43
Anterior Petrosal [Kawase] Approach to Meckel's Cave Meningioma: 2-Dimensional Operative Video. 61
33475720 2021
44
Uveal Melanoma Metastatic to the Cavernous Sinus: A Case Report. 61
32732542 2021
45
SWI/SNF deficient central nervous system neoplasms. 61
33762087 2021
46
Metastases to meningioma-review and meta-analysis. 61
33389125 2021
47
Can Ophthalmologic Examination Predict Abducens Nerve Recovery After Endoscopic Skull Base Surgery? 61
32809233 2021
48
Chordoma and meningioma arising as a collision tumor in the petroclival region: Case report and literature review. 61
33749579 2021
49
Risk factor for cerebrospinal fluid leak after endoscopic endonasal skull base surgery: a single-center experience. 61
33733997 2021
50
Aberrant expression of thyroid transcription factor-1 in meningeal solitary fibrous tumor/hemangiopericytoma. 61
33666786 2021

Variations for Intracranial Meningioma

Expression for Intracranial Meningioma

Search GEO for disease gene expression data for Intracranial Meningioma.

Pathways for Intracranial Meningioma

Pathways related to Intracranial Meningioma according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.49 PCNA MSH2 MLH1 GSTP1 CDKN2A
2 12.42 MSH2 MLH1 IGF2 GSTP1 ESR1 DVL3
3
Show member pathways
12.4 PCNA MSH2 MGMT ESR1
4
Show member pathways
12.17 PGR MLH1 IGF2 GSTP1 ESR1 DVL3
5 11.77 PCNA MSH2 MLH1
6 11.68 MGMT IGF2 CDKN2A
7 11.64 PCNA MSH2 MLH1 MKI67 MGMT GSTP1
8
Show member pathways
11.59 PCNA MSH2 MLH1
9 11.49 MSH2 MLH1 GSTP1 CDKN2A
10
Show member pathways
11.2 MSH2 MLH1 MGMT GSTP1
11 11.03 PGR MLH1
12 11.01 MSH2 MLH1 GSTP1
13
Show member pathways
11 MGMT GSTP1

GO Terms for Intracranial Meningioma

Cellular components related to Intracranial Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.56 PGR PCNA MSH2 MLH1 MKI67 MGMT
2 condensed chromosome GO:0000793 9.16 MLH1 MKI67
3 mismatch repair complex GO:0032300 8.62 MSH2 MLH1

Biological processes related to Intracranial Meningioma according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.93 PGR IGF2 ESR1 DVL3 CDKN2A
2 cellular response to DNA damage stimulus GO:0006974 9.81 PCNA MSH2 MLH1 MGMT
3 DNA repair GO:0006281 9.76 PCNA MSH2 MLH1 MGMT
4 response to estradiol GO:0032355 9.61 PCNA GSTP1 ESR1
5 positive regulation of DNA repair GO:0045739 9.55 PCNA MGMT
6 steroid hormone mediated signaling pathway GO:0043401 9.52 PGR ESR1
7 isotype switching GO:0045190 9.49 MSH2 MLH1
8 somatic hypermutation of immunoglobulin genes GO:0016446 9.48 MSH2 MLH1
9 protein localization to chromatin GO:0071168 9.4 MSH2 ESR1
10 intracellular steroid hormone receptor signaling pathway GO:0030518 9.37 PGR ESR1
11 positive regulation of isotype switching to IgG isotypes GO:0048304 9.32 MSH2 MLH1
12 positive regulation of isotype switching to IgA isotypes GO:0048298 9.26 MSH2 MLH1
13 somatic recombination of immunoglobulin gene segments GO:0016447 9.16 MSH2 MLH1
14 mismatch repair GO:0006298 9.13 PCNA MSH2 MLH1
15 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 8.62 MSH2 MLH1

Molecular functions related to Intracranial Meningioma according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.87 PGR PCNA MSH2 MKI67 MGMT ESR1
2 protein kinase binding GO:0019901 9.73 MSH2 GSTP1 ESR1 CDKN2A
3 chromatin binding GO:0003682 9.71 PCNA MSH2 MLH1 ESR1
4 protein C-terminus binding GO:0008022 9.67 PCNA MSH2 MKI67
5 steroid binding GO:0005496 9.48 PGR ESR1
6 steroid hormone receptor activity GO:0003707 9.46 PGR ESR1
7 mismatched DNA binding GO:0030983 9.37 MSH2 MLH1
8 MutLalpha complex binding GO:0032405 9.26 PCNA MSH2
9 guanine/thymine mispair binding GO:0032137 9.16 MSH2 MLH1
10 enzyme binding GO:0019899 9.02 PGR PCNA MSH2 MLH1 ESR1
11 dinucleotide insertion or deletion binding GO:0032139 8.96 PCNA MSH2

Sources for Intracranial Meningioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....